Form 4: Rapport CSO Granted 103,000 Stock Options

Rapport Therapeutics' Chief Scientific Officer, David Bredt, was granted 103,000 stock options with an exercise price of $27.75.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc. (RAPP), was granted 103,000 stock options.
• The options have an exercise price of $27.75 per share.
• The options were granted on February 2, 2026, and are set to expire on February 2, 2036.
• The underlying shares will vest in 48 equal monthly installments following January 1, 2026, contingent on Mr. Bredt's continued service to the company.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management's long-term commitment and alignment with shareholder interests through equity compensation, which is standard practice for retaining key talent.

Positives

• The grant of stock options to the Chief Scientific Officer aligns his incentives with long-term shareholder value creation.
• A 10-year expiration period for the options provides a substantial long-term incentive horizon for the executive.

Negatives

• There is no immediate cash inflow for the officer, as these are options and not immediately exercisable shares.
• The vesting schedule ties the officer to the company for four years, which, while a retention mechanism, limits immediate liquidity from these options.

Risks

• The value of the options is contingent on Rapport Therapeutics' stock price exceeding the exercise price of $27.75 in the future.
• Vesting of the options is subject to Mr. Bredt's continued service, meaning the options could be forfeited if his employment ceases before full vesting.

Future Outlook

This filing primarily reports a past transaction related to executive compensation. It implies a long-term commitment from the Chief Scientific Officer, which could contribute to stability in the company's scientific leadership.

Industry Context

StockSavvy.ai notes that equity compensation, particularly stock options with vesting schedules, is a standard practice in the biotechnology and pharmaceutical industries. This approach is commonly used to attract, retain, and incentivize key scientific and executive talent, aligning management's interests with long-term shareholder value creation, similar to practices observed at companies like Moderna (MRNA) or BioNTech (BNTX) during their growth phases.

Comparison to Industry Standards

• The grant of 103,000 stock options to a Chief Scientific Officer is a common form of executive compensation in the biotech sector, comparable to grants seen at similar-stage companies.
• An exercise price of $27.75 suggests the options were granted at or near the market price on the grant date, which is standard for incentive stock options.
• A 10-year expiration period is typical for employee stock options, providing ample time for value appreciation.
• A 4-year monthly vesting schedule (48 installments) is a standard retention mechanism, similar to what is observed at companies like Vertex Pharmaceuticals (VRTX) or Regeneron (REGN) for their key scientific personnel.

Stakeholder Impact

• Shareholders: Potential for increased alignment of the Chief Scientific Officer's interests with long-term shareholder value. There is a standard dilution risk if options are exercised in the future, which is typical for equity compensation plans.
• Employees: May signal stability in the company's scientific leadership.

Next Steps

• Continued service of David Bredt to ensure the vesting of options.
• Potential future exercise of options by David Bredt if the stock price appreciates above $27.75.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive, which is a standard compensation practice. It does not contain information that would fundamentally alter the investment thesis for Rapport Therapeutics, Inc. While it signals continued commitment from the Chief Scientific Officer, it doesn't provide new financial performance data or strategic shifts that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Rapport Therapeutics, RAPP, Stock Options, Insider Transaction, Form 4, David Bredt, Chief Scientific Officer, Equity Compensation, Vesting